Global cGMP Active Pharmaceutical Ingredient (API) Manufacturing, Comprehensive Dossier Support (DMF/CEP), and Advanced Small Molecule Technical Solutions for Targeted Oncology Formulations
Explore our primary pharmaceutical ingredients and commercial-grade synthetic peptides manufactured under strict regulatory compliance and global quality standards.
Afatinib (commonly commercialized as Afatinib Dimaleate, CAS Registry Number: 850140-73-7) represents a cornerstone second-generation, irreversible ErbB family tyrosine kinase inhibitor (TKI). Unlike first-generation reversible EGFR TKIs such as Gefitinib and Erlotinib, Afatinib forms a covalent, irreversible bond with the ATP-binding sites of EGFR (ErbB1), HER2 (ErbB2), and ErbB4 (HER4), alongside transphosphorylated intracellular domains. As global oncology drug developers strive for cost-effective generic formulations and advanced combination clinical trials, sourcing high-purity, cGMP-grade Afatinib Active Pharmaceutical Ingredient (API) with robust solid-state consistency has become paramount.
| Parameter | Technical Specification / Property Value | Analytical Method |
|---|---|---|
| Chemical Name | (2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[((3S)-tetrahydro-3-furanyl)oxy]-6-quinazolinyl}-4-(dimethylamino)-2-butenamide dimaleate | IUPAC Nomenclature |
| CAS Number | 850140-72-6 (Free Base) / 850140-73-7 (Dimaleate Salt) | CAS Registry |
| Molecular Formula | C24H25ClFN5O3 · 2(C4H4O4) | Mass Spectrometry (HRMS) |
| Molecular Weight | 718.08 g/mol (Dimaleate form) | Theoretical / MS Verification |
| Physical Appearance | White to off-white or pale yellow crystalline powder | Visual / Colorimetric |
| Solubility Profile | Highly soluble in DMSO, sparingly soluble in water (pH-dependent), practically insoluble in non-polar organic solvents | OECD Guideline 105 |
| Polymorphism | Thermodynamically stable Form A (Verified via XRPD) | X-Ray Powder Diffraction (XRPD) / DSC |
| Residual Solvents | Conforms strictly to ICH Q3C(R6) limits (Ethanol, Isopropanol, THF < limits) | Headspace GC-MS |
The target market for EGFR inhibitors is undergoing a rapid evolution. Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancer diagnoses worldwide. Among non-Asian NSCLC patient cohorts, EGFR mutations occur in 10-15% of cases, whereas in Asian populations, mutation prevalence reaches up to 40-50%. Afatinib's unique pharmacological profile—specifically its regulatory approvals for first-line treatment of patients with metastatic NSCLC harboring non-resistant EGFR mutations (exons 19 deletion or exon 21 L858R substitution) and resistant mutations like S768I, L861Q, and G719X—positions it as an indispensable pharmaceutical asset.
With key compound patents expiring across North America, Europe, and Asia-Pacific regions, drug product manufacturers are aggressively filing Abbreviated New Drug Applications (ANDAs). Sourcing API from vetted manufacturers with ready Drug Master Files (DMF) shortens time-to-market by 12–18 months.
Global regulatory agencies (FDA, EMA, PMDA) have instituted stringent screening protocols for N-nitrosamine impurities in secondary and tertiary amine containing active ingredients. Advanced suppliers must validate synthesis routes that prevent NDMA/NDEA formation during downstream purification.
Pharmaceutical brands are moving away from single-source reliance. Establishing primary and secondary qualified suppliers in compliant jurisdictions (utilizing state-of-the-art 250,000+ sqm standard facilities) ensures operational resilience against geopolitical and logistics disruptions.
The commercial chemical synthesis of Afatinib Dimaleate involves a multi-step sequence starting from 4-chloro-6,7-substituted quinazoline intermediates. Critical Quality Attributes (CQAs) must be meticulously monitored via Process Analytical Technology (PAT) to control regio-isomerism, maintain precise stereochemistry at the (3S)-tetrahydrofuran center, and force the quantitative formation of the trans-alkenamide geometric isomer.
During synthetic optimization, particular focus is applied to controlling the following potential process-related impurities:
Because Afatinib Dimaleate exhibits pH-dependent solubility, particle size distribution (PSD) directly influences in vitro dissolution kinetics and in vivo bioequivalence (BE) testing against the innovator drug product (Gilotrif / Giotrif).
Custom jet-milling systems allow tight control over particle metrics: d10 ≤ 2.5 μm, d50 ≤ 10 μm, and d90 ≤ 25 μm, eliminating dissolution rate limitations in oral dosage form development.
X-Ray Powder Diffraction (XRPD) patterns are batch-certified to ensure 100% phase purity of Form A, preventing solvent-induced polymorph conversion during wet granulation manufacturing processes.
Gentolex’s overarching goal is to create seamless global opportunities connecting pharmaceutical researchers, generic manufacturers, and biotech innovators with guaranteed product quality and technical excellence. Up to date, Gentolex Group has served clients across more than 10 countries. To provide responsive localization, dedicated international representative offices are established in Mexico and South Africa.
Our main integrated services focus on supplying high-purity small molecule APIs, standard and custom peptides APIs, Finished Dosage Form (FDF) licensing out, technical consultation, laboratory setup, and global contract sourcing & supply chain optimization.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions for small molecules and complex compounds.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Complete regulatory documentation supported worldwide.
Full-spectrum contract chemistry, route scouting, process optimization, impurity isolation, structural characterization, and analytical method validation tailored for global pharma clients.
For clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide streamlined procurement services backed by our reliable audit-verified supply chain network.
Navigating regulatory filing procedures requires customized documentation and local support infrastructure. Gentolex bridges international supply requirements with local regulatory demands in key markets:
With dedicated local representation in Mexico, we provide localized support for COFEPRIS registration, bioequivalence sample clearing, regulatory dossier translation, and local stability study protocols under Zone IVB conditions.
Our established regional presence in South Africa facilitates direct engagement with pharmaceutical formulators operating under SAHPRA guidelines, guaranteeing streamlined import permits, fast-track tech transfers, and security of supply.
We provide full eCTD format Drug Master Files (DMF), Certificate of Suitability (CEP) documentation, open-part/closed-part dossiers, and complete elemental impurity risk evaluations (ICH Q3D) for seamless integration into ANDA/MAA applications.
As clinical research advances, the application of targeted therapies expanded beyond single-agent regimens. Gentolex is at the forefront of supporting next-generation oncology applications and specialized formulations through ongoing R&D initiatives:
Supporting investigational combination protocols linking Afatinib with immunotherapeutic monoclonal antibodies or secondary pathway TKIs (MET inhibitors) to overcome acquired T790M or C797S resistance mutations.
Developing specialized API particle characteristics suitable for lipid nanoparticle (LNP) encapsulation and polymeric micelles, designed to enhance blood-brain barrier (BBB) penetration for brain metastatic NSCLC cases.
Implementing micro-reactor continuous synthesis for hazardous coupling steps, significantly reducing solvent consumption, improving atom economy, and securing a lower carbon footprint across bulk API production.
Stay informed with the latest research updates, product developments, and synthetic advancements from Gentolex Group’s specialized R&D division.
Introduction to Selank Acetate API: Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous peptide tuftsin...
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier: As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and life science labs...
View Details
Introduction: BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation. As a specialized peptide active ingredient...
View Details
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment, has attracted global interest...
View Details
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure and supporting cellular bioenergetics, SS-31 has gained significant clinical research interest...
View DetailsEssential technical, regulatory, and commercial information for API procurement officers, QA/QC directors, and pharmaceutical formulators.
Discover our extended catalog of APIs, custom peptide sequences, plasticizers, and fine industrial chemical raw materials.
Buy Tributyl citrate TBC 77-94-1 for good environmental plasticizers Manufacturer, Suppliers
View Details
Buy Tirzepatide 15 mg/vial powder for injection for weight loss Manufacturer, Exporters
View Details
